APPLICATIONS AND LIMITATIONS OF MEASUREMENT OF 15-KETO,13,14-DIHYDRO PROSTAGLANDIN-E2 IN HUMAN-BLOOD BY RADIOIMMUNOASSAY

It has been anticipated that the inherent limitations of radioimmunoassays [RIA] for prostaglandin [PG] E would be obviated by assays for its major circulating metabolite, 15-keto, 13,14-dihydro PGE2 (KH2-PGE2) which has a longer half-life in blood. The effects of PGE2 infusion and alterations in lipolysis were examined in vivo, and of clotting, prolonged storage and hemolysis in vitro, on KH2-PGE2 immunoreactivity in unextracted human plasma and serum samples. Indeed KH2-PGE2 levels rose several hundred fold during infusions of PGE2 at doses which cause little or no increment in peripheral PGE levels. During stimulation of lipolysis by infusions of epinephrine, apparent KH2-PGE2 levels rose 5-fold. The dilution curve of plasma obtained during stimulation of lipolysis was not parallel to the standard curve; furthermore, apparent KH2-PGE2 levels were correlated strongly with free fatty acid (FFA) levels, suggesting that FFA''s cross-reacted in the RIA weakly but significantly due to their very high molar concentration in blood. Clotting and prolonged storage of samples, but not hemolysis, also caused marked apparent increments in KH2-PGE2 levels. Competition curves using dilutions of such samples were again not parallel to the standard curves in plasma or buffer, but resembled dilution curves of samples containing high levels of FFA. Handling of human blood samples for KH2-PGE2 measurement must be carefully standardized to avoid significant artifacts which presumably are due in part to fatty acids released from triglyceride stores in vivo or from disrupted membrane phospholipids in vitro. Unextracted plasma appears to be unsatisfactory for use in this RIA.